Home > Insider Trading > Filing (0001104659-18-042315)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674365	Aptinyx Inc.	APTX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1365617	J Patrick Heron	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1655827	Frazier Life Sciences Viii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1698755	Fhm Life Sciences Viii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1698823	Fhm Life Sciences Viii, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-06-25	1,047,450	$0.00	1,047,450	No	4	C	Direct
Common Stock	Acquisiton	2018-06-25	1,197,076	$0.00	2,244,526	No	4	C	Direct
Common Stock	Acquisiton	2018-06-25	795,553	$0.00	3,040,079	No	4	C	Direct
Common Stock	Acquisiton	2018-06-25	150,000	$16.00	3,190,079	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2018-06-25	28,895,188	$0.00	1,047,450	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2018-06-25	33,022,786	$0.00	1,197,076	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-25	21,946,301	$0.00	795,553	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.
On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.